How to Get Rezdiffra (Resmetirom) in New Mexico

What Rezdiffra Is and Why It Matters for New Mexico Patients

Rezdiffra (resmetirom) is the first drug the FDA has approved specifically for metabolic dysfunction-associated steatohepatitis with liver fibrosis. The March 2024 accelerated approval covers adults with noncirrhotic MASH and moderate to advanced fibrosis (stages F1b through F3), making it the only targeted pharmacotherapy for this condition [1].

New Mexico carries a disproportionate burden of liver disease. Data from the CDC's chronic liver disease surveillance show that the state's age-adjusted mortality rate from chronic liver disease ranks among the highest in the nation [2]. Metabolic risk factors drive much of this burden. A 2023 analysis published in Hepatology estimated that MASH prevalence in the U.S. adult population is approximately 5.3%, translating to roughly 56,000 adults in New Mexico based on census figures [3]. The AACE 2023 clinical practice guideline for NAFLD/MASH recommends pharmacotherapy for patients with biopsy-proven MASH and fibrosis stage F2 or higher, and notes that THR-β agonists represent a mechanistically distinct treatment class [4].

Because Rezdiffra targets THR-β, it lowers hepatic fat through a different pathway than GLP-1 receptor agonists. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared with 9.7% on placebo (P<0.001) [5]. That separation was clinically meaningful: fibrosis improvement by at least one stage occurred in 25.9% of the 100 mg group vs. 14.2% on placebo [5].

Telehealth Prescribing in New Mexico

New Mexico permits telehealth prescribing of Rezdiffra. The state's Telehealth Act (NMSA 24-25-3) allows licensed providers to establish a patient-provider relationship via synchronous audio-video visits and prescribe medications, including specialty drugs, without requiring a prior in-person exam.

This matters for patients in rural and frontier counties. According to the AAFP's physician workforce data, roughly 33 of New Mexico's 33 counties qualify as medically underserved areas, and gastroenterology and hepatology specialists concentrate heavily in Albuquerque and Las Cruces [6]. Telehealth extends access across the state.

A telehealth visit for Rezdiffra typically follows the same clinical workflow as an in-person encounter. The prescriber reviews imaging or biopsy confirming MASH with fibrosis, orders baseline labs, counsels the patient on dosing, and transmits the prescription electronically to a specialty or 503A pharmacy. The FDA prescribing information does not restrict telehealth prescribing for resmetirom, leaving the decision to state law and clinical judgment [1].

New Mexico's Board of Medical Examiners and Board of Nursing both recognize telehealth as a valid modality for prescribing. NPs in New Mexico hold full practice authority under state statute, meaning they can independently diagnose MASH, order fibrosis staging, and prescribe Rezdiffra without physician oversight [7].

Who Can Prescribe Rezdiffra in New Mexico

Three types of licensed providers can write a Rezdiffra prescription in New Mexico. MDs and DOs have unrestricted prescriptive authority. Nurse practitioners hold independent practice authority per the NM Nursing Practice Act, allowing them to prescribe without a collaborative agreement [7]. PAs may prescribe under a supervising physician's delegation, per the New Mexico Medical Practice Act.

In practice, hepatologists and gastroenterologists initiate most Rezdiffra prescriptions because they perform the fibrosis staging workup. Primary care providers and endocrinologists can also prescribe when imaging-based fibrosis scores (FibroScan, MR elastography, or the FIB-4 index) confirm eligibility. The AASLD 2023 practice guidance on NAFLD endorses noninvasive testing pathways for fibrosis assessment, reducing the need for liver biopsy in many patients [8].

A referral is not legally required under New Mexico law, though some insurers mandate hepatology or GI consultation as part of their prior authorization criteria. Confirm with your plan before scheduling.

Required Labs Before Starting Rezdiffra

The FDA label mandates specific laboratory monitoring before and during resmetirom therapy [1]. Before the first dose, providers must obtain:

• Hepatic function panel (ALT, AST, total bilirubin, alkaline phosphatase). Resmetirom is contraindicated if baseline ALT or AST exceeds 5 times the upper limit of normal.
• Thyroid function tests (TSH, free T4). Resmetirom's THR-β selectivity spares the heart, but monitoring ensures no clinically significant thyroid axis disruption [9].
• Lipid panel. In MAESTRO-NASH, resmetirom reduced LDL cholesterol by approximately 14% at 100 mg, a secondary benefit documented at 52 weeks in the NEJM publication [5].
• Complete blood count and serum creatinine, per standard hepatology workup.
• FIB-4 index or FibroScan to confirm fibrosis stage. The AASLD practice guidance recommends FIB-4 as an initial screening tool, with values above 1.3 prompting advanced imaging [8].

After initiation, repeat liver function tests at 3, 6, and 12 months during the first year. The FDA label specifically warns providers to discontinue resmetirom if ALT or AST rises above 5 times the upper limit of normal during treatment, or if the patient develops signs of hepatic decompensation [1].

Pharmacy Access and 503A Compounding in New Mexico

Rezdiffra is distributed through specialty pharmacy channels. Madrigal Pharmaceuticals partnered with a limited network of specialty pharmacies at launch, though distribution has expanded through 2025 and into 2026 [10]. New Mexico patients can fill prescriptions through national specialty pharmacies that ship to the state.

New Mexico also permits 503A compounding pharmacies to compound and dispense resmetirom pursuant to individual patient prescriptions. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed 503A pharmacy may compound a drug when a prescriber determines the commercially available product does not meet the patient's clinical need [11]. This pathway may reduce out-of-pocket costs for patients who lack insurance coverage.

The New Mexico Board of Pharmacy licenses and inspects all compounding pharmacies operating within the state. Out-of-state 503A pharmacies may ship into New Mexico if they hold a nonresident pharmacy license issued by the NM Board [12].

Patients should confirm that any 503A-compounded resmetirom uses pharmaceutical-grade ingredients and meets USP compounding standards. The FDA's compounding guidance clarifies the distinction between traditional compounding and manufacturing [11].

Insurance Coverage and Prior Authorization in New Mexico

Commercial insurance plans in New Mexico increasingly cover Rezdiffra, but prior authorization is nearly universal. The list price for brand-name Rezdiffra is approximately $47,400 per year, making PA a standard gatekeeping step [10].

New Mexico Medicaid does not cover Rezdiffra as of May 2026. Patients enrolled in Centennial Care (managed Medicaid) or fee-for-service Medicaid will need alternative pathways, including Madrigal's patient assistance program or 503A compounding.

For commercial plans, prior authorization documentation typically includes:

• Confirmed MASH diagnosis by biopsy or validated noninvasive composite score (e.g., FAST score, NFS, or FibroScan with CAP). The AASLD guidance endorses several noninvasive pathways [8].
• Fibrosis staging showing F1b, F2, or F3.
• Documentation of lifestyle modification (diet and exercise counseling), as most payers require evidence of behavioral intervention before approving pharmacotherapy.
• Baseline lab results (hepatic panel, TSH, lipids).
• Prescriber specialty or consultation note from a hepatologist/gastroenterologist.

Turn-around times for PA decisions in New Mexico follow state prompt-payment rules: standard decisions within 15 business days, expedited (urgent) within 72 hours. Appeals processes vary by carrier. Blue Cross Blue Shield of New Mexico, Presbyterian Health Plan, and Western Sky Community Care each maintain their own formulary criteria.

Madrigal offers a copay assistance program that may reduce out-of-pocket costs for commercially insured patients. Eligible patients can pay as little as $0 per month, subject to annual caps [10].

Dosing, Titration, and Ongoing Monitoring

Rezdiffra follows a fixed two-step dosing schedule per the FDA-approved prescribing information [1]:

• Months 1 through 3: 80 mg once daily, taken with food.
• Month 4 onward: 100 mg once daily, taken with food.

The dose escalation is not optional. The MAESTRO-NASH trial evaluated both the 80 mg and 100 mg doses as distinct treatment arms and found that the 100 mg dose produced numerically higher rates of MASH resolution (29.9% vs. 25.9%) and fibrosis improvement (25.9% vs. 24.2%) at 52 weeks [5]. The 80 mg run-in period allows hepatic adaptation and reduces early gastrointestinal side effects.

Common adverse reactions in the trial included diarrhea (26.5% vs. 17.2% placebo), nausea (18.2% vs. 13.6%), and abdominal pain. Most GI symptoms were mild to moderate and resolved within the first 4 to 6 weeks [5]. Gallbladder-related events occurred at higher rates in the resmetirom groups. A pooled safety analysis presented at AASLD's The Liver Meeting 2024 reported cholelithiasis in approximately 3.2% of resmetirom-treated patients [13].

Drug interactions are limited. Resmetirom is metabolized primarily by CYP2C8 and CYP3A4. The FDA label warns against concomitant use with strong CYP2C8 inhibitors (e.g., gemfibrozil) and recommends monitoring with moderate inhibitors [1]. Statins, which many MASH patients take, do not require dose adjustment. The LDL-lowering effect of resmetirom (approximately 14% reduction) is additive with statin therapy, as documented in the MAESTRO-NASH secondary endpoints [5].

Timeline From First Visit to First Dose in New Mexico

The time from initial consultation to receiving Rezdiffra depends on several variables. A typical timeline for a New Mexico patient:

Week 1: Telehealth or in-person visit. Provider reviews existing imaging, orders FibroScan or FIB-4 calculation if not already done, and draws baseline labs. The AASLD noninvasive testing pathway can yield fibrosis staging within a single visit when FibroScan is available [8].

Week 2: Lab and imaging results return. If fibrosis staging confirms F1b through F3, the provider submits a prescription and initiates prior authorization.

Weeks 2 through 4: Prior authorization processing. Standard PA in New Mexico takes up to 15 business days. Expedited review (72 hours) applies if the provider documents clinical urgency, such as rapidly progressing fibrosis.

Week 3 through 5: Specialty pharmacy ships Rezdiffra. Most national specialty pharmacies deliver within 3 to 5 business days after PA approval. Patients using 503A compounding pharmacies may receive the drug faster, as compounding pharmacies do not depend on the limited specialty distribution network.

Total elapsed time: 3 to 5 weeks for commercially insured patients with straightforward PA. Without insurance coverage, the 503A pathway or manufacturer copay card can shorten this to 1 to 2 weeks.

Transferring a Rezdiffra Prescription to New Mexico

Patients relocating to New Mexico or traveling from another state can transfer an existing Rezdiffra prescription. New Mexico's Board of Pharmacy allows prescription transfers between licensed pharmacies under standard transfer protocols. The receiving pharmacy must hold a valid New Mexico license (resident or nonresident) [12].

For specialty pharmacy prescriptions, the process differs slightly. Most specialty pharmacies operate under a single national license and can update the shipping address without a formal transfer. Contact the dispensing pharmacy directly.

If transferring from a provider outside New Mexico, you will need a New Mexico-licensed prescriber to assume care. The new provider should review your fibrosis staging documentation, recent labs, and treatment response. A telehealth visit satisfies this requirement under the Telehealth Act, so you do not need to wait for an in-person appointment [14].

Patients on active Rezdiffra therapy should avoid gaps exceeding 7 days. Dose re-titration is not required after brief interruptions per the prescribing information, but providers may re-check liver function tests if the gap exceeds 4 weeks [1].

How Rezdiffra Fits Into MASH Treatment in New Mexico

Resmetirom does not replace lifestyle modification. It adds targeted hepatic fat reduction on top of diet, exercise, and metabolic risk factor management. The Endocrine Society's 2023 clinical practice guideline recommends a 7 to 10% body weight reduction as first-line therapy for MASH, with pharmacotherapy reserved for patients who have fibrosis despite lifestyle changes [15].

For New Mexico patients already on GLP-1 receptor agonists (semaglutide, tirzepatide) for weight management or type 2 diabetes, resmetirom offers a complementary mechanism. GLP-1 agonists reduce hepatic steatosis primarily through weight loss and improved insulin sensitivity. Resmetirom acts directly on THR-β in the liver, increasing mitochondrial fatty acid oxidation [16]. The combination has not been studied in a dedicated randomized trial, but the MAESTRO-NASH subgroup analyses did not exclude patients on background GLP-1 therapy [5].

Pioglitazone and vitamin E remain the only other agents with evidence supporting MASH resolution, per the AASLD 2023 guidance [8]. Pioglitazone carries weight gain and heart failure risks. Vitamin E lacks fibrosis improvement data. Resmetirom is the only approved option that addresses both MASH resolution and fibrosis regression in a single oral agent, based on the MAESTRO-NASH primary endpoints: 25.9% fibrosis improvement at 100 mg vs. 14.2% placebo (P<0.001) [5].